Viloxazine: Difference between revisions
| [pending revision] | [pending revision] |
MDElliottMD (talk | contribs) Remove Category:Psychostimulants tag (second pass after duplicate-tag situation) |
MDElliottMD (talk | contribs) Tier 1 taxonomy consolidation: removed redundant Category:Norepinephrine Reuptake Inhibitors (canonical already present) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 2: | Line 2: | ||
| brand = Qelbree | | brand = Qelbree | ||
| classes = Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism, non-stimulant ADHD agent | | classes = Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism, non-stimulant ADHD agent | ||
| mechanism = Selective NET inhibitor (no significant DAT activity | | mechanism = Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine. | ||
| uses = ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) | | uses = ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) | ||
| starting_dose = Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. | | starting_dose = Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. | ||
| Line 13: | Line 13: | ||
| bioavailability = Adequate oral bioavailability with extended-release formulation | | bioavailability = Adequate oral bioavailability with extended-release formulation | ||
| pregnancy = Limited data | | pregnancy = Limited data | ||
| legal = Rx | | legal = Rx, '''not a controlled substance''' (no DEA scheduling) | ||
| intro = '''Viloxazine''' (brand name Qelbree) is an extended-release norepinephrine reuptake inhibitor FDA-approved in 2021 for ADHD in children 6 and older, and in 2022 for adults. Originally developed as an antidepressant in Europe in the 1970s (withdrawn for commercial reasons), it was repurposed for ADHD. Like atomoxetine, viloxazine is a non-stimulant alternative that is '''not a controlled substance'''. However, viloxazine has a more complex pharmacology than atomoxetine | | intro = '''Viloxazine''' (brand name Qelbree) is an extended-release norepinephrine reuptake inhibitor FDA-approved in 2021 for ADHD in children 6 and older, and in 2022 for adults. Originally developed as an antidepressant in Europe in the 1970s (withdrawn for commercial reasons), it was repurposed for ADHD. Like atomoxetine, viloxazine is a non-stimulant alternative that is '''not a controlled substance'''. However, viloxazine has a more complex pharmacology than atomoxetine, beyond pure NET inhibition, it has 5HT1A partial agonism and 5HT2B/5HT7 antagonism, which may underlie faster onset (1-2 weeks vs atomoxetine's 4-6 weeks) and possibly different efficacy. | ||
Useful when stimulants are contraindicated, undesirable, or insufficient. Can be combined with stimulants. | Useful when stimulants are contraindicated, undesirable, or insufficient. Can be combined with stimulants. | ||
| Line 25: | Line 25: | ||
[[Category:Antidepressants]] | [[Category:Antidepressants]] | ||
[[Category:Non-stimulant ADHD Medicines]] | [[Category:Non-stimulant ADHD Medicines]] | ||
Latest revision as of 17:02, 21 May 2026
Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism, non-stimulant ADHD agent
Viloxazine
Qelbree
Viloxazine (brand name Qelbree) is an extended-release norepinephrine reuptake inhibitor FDA-approved in 2021 for ADHD in children 6 and older, and in 2022 for adults. Originally developed as an antidepressant in Europe in the 1970s (withdrawn for commercial reasons), it was repurposed for ADHD. Like atomoxetine, viloxazine is a non-stimulant alternative that is not a controlled substance. However, viloxazine has a more complex pharmacology than atomoxetine, beyond pure NET inhibition, it has 5HT1A partial agonism and 5HT2B/5HT7 antagonism, which may underlie faster onset (1-2 weeks vs atomoxetine's 4-6 weeks) and possibly different efficacy.
Useful when stimulants are contraindicated, undesirable, or insufficient. Can be combined with stimulants.
Selective NET inhibition (Ki ~155 nM). 5HT1A partial agonism, 5HT2B antagonism, 5HT2C inverse agonism, 5HT7 antagonism. Minimal DAT activity (key differentiator from stimulants).
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
Somnolence (most common), decreased appetite, headache, insomnia, fatigue, nausea, irritability. Generally good tolerability. Boxed warning: suicidal ideation in pediatric patients (class warning for SNRIs/antidepressants used in pediatric ADHD).
Pharmacodynamics
Interactions
Fluoxetine via Category:Antidepressants exp n/a/5 outcome n/a (n=1) exp 1.0/5 outcome +33.0 (n=1)
How much experience do you have with this combination (1 a little, 5 a lot)?
How did it go? (-100 worst, +100 best)
- checking this mechanism here
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism, non-stimulant ADHD agent
Pharmacy
Starting dose
Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg.
Preparations
100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food)
US FDA Max
400 mg/d (pediatric); 600 mg/d (adult)
Pharmacology
Routes
Oral
Onset
ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks)
Duration
Daily dosing
Half-life
~7 hours
Bioavailability
Adequate oral bioavailability with extended-release formulation
Pregnancy
Limited data
Legal status
Rx, not a controlled substance (no DEA scheduling)
Purported mechanism
Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine.